[go: up one dir, main page]

WO2011086891A1 - Composition pour faciliter de façon non invasive l'élimination d'un pigment cutané - Google Patents

Composition pour faciliter de façon non invasive l'élimination d'un pigment cutané Download PDF

Info

Publication number
WO2011086891A1
WO2011086891A1 PCT/JP2011/000075 JP2011000075W WO2011086891A1 WO 2011086891 A1 WO2011086891 A1 WO 2011086891A1 JP 2011000075 W JP2011000075 W JP 2011000075W WO 2011086891 A1 WO2011086891 A1 WO 2011086891A1
Authority
WO
WIPO (PCT)
Prior art keywords
skin
ibp
composition
removal
emulsion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2011/000075
Other languages
English (en)
Japanese (ja)
Inventor
猪田利夫
平藤真智子
北島奈津子
横山朋典
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SSP Co Ltd
Nanoegg Research Laboratories Inc
Original Assignee
SSP Co Ltd
Nanoegg Research Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SSP Co Ltd, Nanoegg Research Laboratories Inc filed Critical SSP Co Ltd
Publication of WO2011086891A1 publication Critical patent/WO2011086891A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin

Definitions

  • the present invention relates to a composition for non-invasively promoting the removal of skin pigments.
  • the present invention relates to a composition for non-invasively promoting the removal of melanin in the skin.
  • Pigmentation such as spots, freckles, sunburn, etc., is caused by the deposition of melanin on the skin.
  • Melanin is produced in melanocytes by the action of tyrosinase and the like using tyrosine as a raw material.
  • Such pigmentation is particularly cosmetically unfavorable for women.
  • ⁇ Kojic acid, arbutin, ellagic acid, vitamin C and the like are well known as whitening agents for preventing pigmentation. These compounds suppress melanin production by inhibiting the activity of tyrosinase.
  • non-steroidal anti-inflammatory drugs such as acetylsalicylic acid and mefenamic acid have been reported to suppress melanin production by suppressing the expression of tyrosinase or by inhibiting the activity of tyrosinase (for example, Non-patent documents 1, 2).
  • the conventional whitening agent suppresses melanin production and prevents pigmentation, and the pigment deposited on the skin cannot be positively removed.
  • An object of the present invention is to provide a composition capable of positively removing skin pigments.
  • the present inventor has found that ibuprofen piconol can positively and noninvasively remove skin pigments, and has further studied and completed the present invention.
  • compositions for non-invasively promoting removal of skin pigment, comprising ibuprofen piconol.
  • the composition according to [1] which is a composition for promoting the removal of melanin from the skin.
  • a composition capable of positively and non-invasively removing skin pigments can be provided. Therefore, according to the present invention, it is possible to provide an external preparation for skin that is effective for treatment of pigmentation caused by ultraviolet irradiation, trauma, burns, acne, etc., and removal of tattoos.
  • FIG. 5A is a photograph of the skin of an untreated mouse
  • FIG. 5B is a photograph of the skin of a mouse to which an emulsion containing no IBP is applied.
  • FIG. 6A is a photograph of the skin of a mouse to which an emulsion containing 10% IBP was applied
  • FIG. 6B is a photograph of the skin of a mouse to which a retinoic acid preparation was applied.
  • FIG. 7A is a graph showing the percentage of basal cells expressing Ki-67
  • FIG. 7B is a graph showing the average thickness of the epidermis of each individual.
  • composition of the present invention is a composition for actively and non-invasively removing skin pigments, and is characterized by containing ibuprofen piconol as an active ingredient.
  • the composition of the present invention may contain other optional components.
  • skin pigment is not particularly limited, and examples thereof include melanin and pigments artificially fixed in the skin.
  • Non-invasive removal of skin pigment includes discharging the pigment from the skin, decomposing or changing the pigment in the skin, and promoting these.
  • Ibuprofen piconol (2-pyridylmethyl (RS) -2- (4-isobutylphenyl) propionate) is known as a non-steroidal anti-inflammatory drug (NSAIDs) effective for acute eczema, contact dermatitis, atopic dermatitis, etc.
  • NSAIDs non-steroidal anti-inflammatory drug
  • the inventor has found that ibuprofen piconol can positively remove skin pigments. As shown in the Examples, ibuprofen piconol is considered to have little tyrosinase inhibitory action. Therefore, the pigment removal action of ibuprofen piconol is not a passive removal of melanin gradually due to skin turnover while inhibiting melanin production, but actively removes skin pigment (eg melanin) It is estimated that.
  • the content of ibuprofen piconol in the composition of the present invention is not particularly limited, but is preferably 0.01 to 20% by weight or less, particularly preferably in the range of 1 to 10% by weight.
  • ibuprofen piconol contained in the composition of the present invention may be produced by using a known method, a commercially available product may be used.
  • composition of the present invention can be used, for example, as a pharmaceutical, a quasi-drug, or a cosmetic.
  • the composition of the present invention can be administered by any known administration route.
  • the composition of the present invention can be used as a parenteral or oral administration agent.
  • parenteral dosage forms include extracts, plasters, spirits, suppositories, suspensions, tinctures, ointments, poultices, liniments, lotions, aerosols, eye drops, injections Agents and the like.
  • dosage forms for oral administration include tablets, capsules, powders, fine granules, solutions, troches, jellies and the like.
  • composition of the present invention can also be in the form of a cosmetic composition such as lotion, cream, lotion, emulsion, foam, foundation, pack, skin cleanser, shampoo, rinse, conditioner. .
  • a preferred embodiment of the composition of the present invention includes an external preparation for skin.
  • Formulation can be performed by known formulation techniques, and appropriate formulation additives can be added to the formulation.
  • formulation additives include excipients, binders, disintegrants, lubricants, fluidizers, suspending agents, emulsifiers, stabilizers, moisturizing (wetting) agents, preservatives, solvents, dissolution aids. Agents, preservatives, corrigents, sweeteners, pigments, fragrances, propellants and the like.
  • the formulation additive may be appropriately selected within a range not impairing the effects of the present invention, and an appropriate amount may be added.
  • the dose of the composition of the present invention may be appropriately set according to the sex, age, symptom, administration method, number of administrations, and administration timing of the recipient.
  • Indications include, for example, patients with liver spots, senile pigment spots, Ota nevus, sparrow egg spots, inflammatory pigmentation, frictional dermatosis, petal pigment spots, or the prevention of these diseases Is a healthy person. Preferably, it is a patient with pigmentation.
  • composition of the present invention is useful as a pigmentation treatment agent because it actively removes skin pigment.
  • melanin was removed by applying the composition of the present invention to the skin, the amount of melanin in the skin was reduced, and the skin became white.
  • the compositions of the present invention can be used to remove skin pigments.
  • Example 1 Preparation of Formulation According to a method commonly used in the art, an emulsion (base) was prepared by mixing materials having the composition shown in Table 1 below.
  • IBP Ibuprofen piconol
  • guinea pigs were prepared by irradiating colored guinea pigs with melanin pigment-producing cells (Weiser-Maples, 11 weeks old, male; Tokyo Experimental Animal Co., Ltd.) with ultraviolet rays. Specifically, the back of each individual was shaved and UV-A (11 J / cm 2 per day; 617 ⁇ W / cm 2 ⁇ 5 hours) and UV-B (33 mJ / cm 2 per day; 0.55 mW) / Cm 2 ⁇ 1 minute) was repeated once a day for 5 days a week (from Monday to Friday) for a little less than 6 weeks (28 times in total).
  • melanin pigment-producing cells Weiser-Maples, 11 weeks old, male; Tokyo Experimental Animal Co., Ltd.
  • UV-A lamp used was FL20S ⁇ BLB-A (wavelength range 315 to 380 nm, peak wavelength 352 nm; Toshiba Corporation), and the UV-B lamp used UVM-28 (peak wavelength 302 nm; UVP).
  • UVX Digital Radiometer (UVP) was used as the UV illuminance measuring instrument. After the irradiation period, the sample was left for one week in order to suppress the effects of inflammation caused by ultraviolet irradiation.
  • the application area with a size of 2 cm ⁇ 2 cm was set to 6 sections per animal on the back of each individual where pigmentation occurred. After 30 minutes have passed since the hair of each individual's application area is cut, washed with warm water, and excess water is wiped off, a preparation (10% IBP-containing emulsion, retinoic acid preparation, or IBP-free emulsion) is applied to each application area. 30 mg was applied once a day. This formulation was applied 11 times in total for 15 days (1, 2 weeks: Monday to Friday, 3 weeks: Monday). For comparison, an uncoated area (only ultraviolet irradiation) was also provided.
  • FIG. 1 is a photograph of the application start date, the guinea pig back formulation application area on the seventh, eleventh and fifteenth days after the start of application.
  • FIG. 1 is a photograph of the application start date, the guinea pig back formulation application area on the seventh, eleventh and fifteenth days after the start of application.
  • the retinoic acid preparation and the emulsion containing 10% IBP were applied, significant brightness recovery was observed on the 11th day after the start of application.
  • inflammation with redness was observed, but in the region where the 10% IBP-containing emulsion was applied, no such inflammation was observed.
  • the IBP-free emulsion neither lightness recovery nor inflammation was observed as in the non-application area (only UV irradiation).
  • the lightness (L * value) of the skin was measured using a color difference meter (CR-400; Minolta).
  • the measured increase in skin brightness was used as an index of the degree of recovery from pigmentation.
  • the L * value indicates that the larger the value, the whiter the color.
  • the color difference meter used in this example employs the L * a * b * color system.
  • L * a * b * color system lightness is represented by L *
  • chromaticity indicating hue and saturation is represented by a * and b * .
  • a * and b * indicate the color direction
  • a * indicates the red direction
  • -a * indicates the green direction
  • b * indicates the yellow direction
  • -b * indicates the blue direction.
  • the L * value of each application area was measured at 10 locations per application area, and the average value was adopted.
  • the area where the retinoic acid preparation was applied significant brightness recovery was observed on the seventh day from the application start date.
  • the region where the 10% IBP-containing emulsion was applied significant brightness recovery was observed on the ninth day from the application start date.
  • coated the IBP non-containing emulsion the big difference with the non-application area
  • the redness (a * value) of the skin was measured using the above-described color difference meter.
  • the measured change in skin redness was used as an index of the degree of skin inflammation.
  • the a * value indicates that the larger the value, the stronger the redness.
  • the a * value of each coating area was measured at 10 locations per coating area, and the average value was adopted.
  • redness increased significantly from the 4th day to the 11th day after the application start date.
  • the area where the 10% IBP-containing emulsion was applied and the area where the IBP-free emulsion was applied no significant difference was observed from the non-application area.
  • IBP remarkably accelerates the removal of skin pigments without causing a strong skin inflammatory reaction (side effects) known for retinoic acid.
  • the inflammatory reaction caused by ultraviolet irradiation has subsided (confirmed by the a * value), so the skin pigment removal promoting effect by IBP is due to actions other than the anti-inflammatory action of IBP.
  • Tyrosinase inhibition test To examine whether the whitening effect of the composition of the present invention is due to suppression of melanin production, a tyrosinase inhibition test was performed. The tyrosinase inhibition test is described in a paper (Roh, JS et al., “Inhibitory Effects of Active Compounds Isolated from Safflower (Carthamus tinctorius L.) Seeds for Melanogenesis”, Biol. Pharm. Bull., Vol. 27 (2004), No. 12, pp. 1976-1978.).
  • IBP aqueous solution concentration: 0 to 1000 ⁇ M
  • kojic acid 114-00493; Wako Pure Chemical Industries, Ltd.
  • tyrosinase inhibitor a tyrosinase inhibitor
  • FIG. 4 is a graph showing the results of a tyrosinase inhibition test. From this graph, it can be seen that the activity of tyrosinase is inhibited when the concentration of kojic acid increases, but the activity of tyrosinase does not change even when the concentration of IBP increases. That is, it can be seen that IBP has no inhibitory effect on tyrosinase. From this result, it is suggested that the melanin removing action by IBP is not due to suppression of melanin production but due to positive removal of melanin.
  • Ki-67 The cell proliferation activity was evaluated by counting the number of cells expressing the cell proliferation marker Ki-67.
  • Ki-67 is localized around the nucleus of cells in the G1 phase, in the nucleus of cells in the S and G2 phases, and in the chromosome of cells in the M phase. On the other hand, Ki-67 is not expressed in G0 phase cells. For this reason, Ki-67 is often used as a cell proliferation marker. By using this Ki-67, transition from a non-proliferating cell population to a proliferating cell population can be detected.
  • a coating area of 2 cm ⁇ 3 cm was set on the back of four hairless mice (HR-1, 5 weeks old, male; Nippon SLC Co., Ltd.). After washing the application area of each individual with lukewarm water, 30 mg of the above preparation (10% IBP-containing emulsion, retinoic acid preparation or IBP-free emulsion) was applied once a day. This formulation was applied for 5 days. For comparison, no treatment (cleaning only) was also performed.
  • the antigen-stimulation treatment was performed by immersing the slide glass with the section attached in 10 mM citrate buffer (pH 6.0) and heating the citrate buffer using an autoclave. After naturally cooling at room temperature, the slide glass was immersed in 3% H 2 O 2 (MeOH) for 30 minutes and washed with a phosphate buffer (PBS; pH 7.2), so that the intrinsic components contained in the section were included. Sex peroxidase was inactivated.
  • 50 ⁇ L of blocking solution (5% BSA-PBS) was placed on the section and allowed to stand at room temperature for 30 minutes in a wet box (blocking). After removing the blocking solution, 50 ⁇ L of the primary antibody solution was placed on the section and allowed to stand overnight at 4 ° C. in a wet box (primary antibody reaction).
  • the primary antibody solution used was an anti-mouse Ki-67 rat antibody (Dako) diluted 50-fold with 1% BSA-PBS. After washing the section with PBS, 50 ⁇ L of the secondary antibody solution was placed on the section and allowed to stand at room temperature for 1 hour in a wet box (secondary antibody reaction).
  • a labeled polymer (simple stain mouse MAX-PO (Rat); Nichirei Co., Ltd.) bound with Fab ′ of a secondary antibody (animal species: goat) and peroxidase was added with 1% BSA-PBS. Those diluted twice were used. After washing the sections with PBS, color was developed using DAB, nuclear staining (hematoxylin staining) was performed, and the cells were encapsulated.
  • the immunostained sections were observed using an optical microscope (Biozero; Keyence Corporation), and image data of each section was obtained. Using image analysis software (Photoshop; Adobe Systems Inc.), the total number of basal cells contained in each section and the number of basal cells expressing Ki-67 were measured, and Ki-67 was expressed in each section. The percentage of basal cells that were present was determined. The total number of basal cells contained in each section was 316 to 1316 (no treatment: 316 to 1316, IBP-free emulsion: 611 to 1171, 10% IBP-containing emulsion: 351 to 476, retinoic acid preparation: 350 ⁇ 1053).
  • the thickness of the epidermis at 10 locations was measured for each skin piece, and the average value and standard deviation (SD) of the thickness of the epidermis was calculated.
  • FIG. 5 and FIG. 6 are photographs of the immunostained sections.
  • FIG. 5A is a photograph of the skin of an untreated individual
  • FIG. 5B is a photograph of the skin of an individual to which an IBP-free emulsion is applied.
  • FIG. 6A is a photograph of the skin of an individual to which an emulsion containing 10% IBP is applied
  • FIG. 6B is a photograph of the skin of an individual to which a retinoic acid preparation is applied.
  • Ki-67-positive basal cells were observed in the individuals applied with the 10% IBP-containing emulsion or retinoic acid preparation compared to the untreated individuals and the non-IBP-containing emulsion. Number) increased.
  • the epidermis was thicker than in the other individuals.
  • FIG. 7A is a graph showing the percentage of basal cells expressing Ki-67 in each individual. As shown in this graph, about half of the basal cells were Ki-67 positive in the individuals to which the 10% IBP-containing emulsion or retinoic acid preparation was applied. On the other hand, about 20% of the basal cells were Ki-67 positive in the untreated individuals and the individuals to which the IBP-free emulsion was applied. Since Ki-67 is a marker for cell proliferation, it can be seen that cell proliferation is actively carried out in individuals to which a 10% IBP-containing emulsion or retinoic acid preparation was applied. In addition, since the number of Ki-67 positive cells did not increase in individuals coated with an IBP-free emulsion, it is considered that the promotion of cell proliferation is an effect of IBP.
  • FIG. 7B is a graph showing the average thickness of the epidermis of each individual. As shown in this graph, the epidermis was significantly thickened in the individuals to which the retinoic acid preparation was applied, but the epidermis was not thickened in the individuals to which the 10% IBP-containing emulsion was applied.
  • Retinoic acid preparations are used as a whitening agent and an anti-wrinkle agent in hospital prescriptions. Retinoic acid is said to promote skin turnover and thicken the epidermis.
  • the 10% IBP-containing emulsion promoted cell growth but did not thicken the epidermis. This suggests that the whitening effect by IBP is due to a mechanism different from that of retinoic acid.
  • Example 2 IBP was mixed with the emulsion having the composition shown in Table 1 so that the final concentration was 1% or 3%, and a skin external preparation consisting of a 1% IBP-containing emulsion and a skin external preparation consisting of a 3% IBP-containing emulsion were prepared.
  • composition of the present invention can remove skin pigments non-invasively, it is effective as an external skin preparation effective for treatment of pigmentation caused by, for example, ultraviolet irradiation, trauma, burns, acne, and removal of tattoos. Useful.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition pouvant éliminer de façon active un pigment cutané. La composition contient de l'ibuprofène piconol au titre de principe actif, peut éventuellement contenir d'autres composants si nécessaires, et peut constituer un médicament topique efficace dans le traitement de la chromatose provoqué par les rayonnements ultraviolets, les blessures, les brûlures, l'acné, etc.
PCT/JP2011/000075 2010-01-12 2011-01-11 Composition pour faciliter de façon non invasive l'élimination d'un pigment cutané Ceased WO2011086891A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010004250A JP2013082631A (ja) 2010-01-12 2010-01-12 非侵襲的に皮膚の色素の除去を促進するための組成物
JP2010-004250 2010-01-12

Publications (1)

Publication Number Publication Date
WO2011086891A1 true WO2011086891A1 (fr) 2011-07-21

Family

ID=44304169

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2011/000075 Ceased WO2011086891A1 (fr) 2010-01-12 2011-01-11 Composition pour faciliter de façon non invasive l'élimination d'un pigment cutané

Country Status (3)

Country Link
JP (1) JP2013082631A (fr)
TW (1) TW201138761A (fr)
WO (1) WO2011086891A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015010059A (ja) * 2013-06-28 2015-01-19 ロート製薬株式会社 医薬組成物

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5789426B2 (ja) * 2011-06-17 2015-10-07 エスエス製薬株式会社 表皮ターンオーバー促進剤

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62413A (ja) * 1985-06-27 1987-01-06 Pola Chem Ind Inc 化粧料
JPH01199916A (ja) * 1988-02-04 1989-08-11 Sansho Seiyaku Co Ltd 外用剤
WO2002098372A1 (fr) * 2001-06-01 2002-12-12 Masaya Tanaka Composition acide a usage externe et agent accelerant la penetration dans la peau ou analogue d'une preparation cosmetique, d'un agent favorisant la pousse des cheveux et d'une preparation a usage externe contenant chacun ladite composition
JP2005281279A (ja) * 2004-03-31 2005-10-13 Shiseido Co Ltd リパーゼ阻害剤及びニキビ改善用外用剤

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62413A (ja) * 1985-06-27 1987-01-06 Pola Chem Ind Inc 化粧料
JPH01199916A (ja) * 1988-02-04 1989-08-11 Sansho Seiyaku Co Ltd 外用剤
WO2002098372A1 (fr) * 2001-06-01 2002-12-12 Masaya Tanaka Composition acide a usage externe et agent accelerant la penetration dans la peau ou analogue d'une preparation cosmetique, d'un agent favorisant la pousse des cheveux et d'une preparation a usage externe contenant chacun ladite composition
JP2005281279A (ja) * 2004-03-31 2005-10-13 Shiseido Co Ltd リパーゼ阻害剤及びニキビ改善用外用剤

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015010059A (ja) * 2013-06-28 2015-01-19 ロート製薬株式会社 医薬組成物

Also Published As

Publication number Publication date
JP2013082631A (ja) 2013-05-09
TW201138761A (en) 2011-11-16

Similar Documents

Publication Publication Date Title
JP5781443B2 (ja) 皮膚色素沈着の障害および状態を処置するカルシウム封鎖組成物および方法
JP3706615B2 (ja) 肌のしわ予防及び低減のための組成物
JP2012515218A5 (fr)
EP3978020A1 (fr) Composition pour la peau
JP2004538308A (ja) 電子伝達剤のリン酸誘導体を用いた皮膚治療
KR101858095B1 (ko) 커큐민을 포함하는 강황 추출물을 유효 성분으로 포함하는 피부 미백, 주름 형성 억제, 및 소양증 완화용 화장품 조성물
KR20100128733A (ko) 편백다당체를 함유하는 피부 외용제 조성물
JPWO2017138652A1 (ja) メラニン分解抑制剤
JPH06279227A (ja) 皮膚外用製剤及び化粧料
EP3145480A1 (fr) Preparations cosmetiques et/ou dermatologiques extemporanees
KR101249889B1 (ko) 규산염을 함유하는 화장료 조성물
EP3142682A1 (fr) Association d'un tétrapeptide et d'un glycéryl ester pour le traitement de l'alopécie androgénique.
KR101939112B1 (ko) 진세노사이드 ｆ１을 함유하는 피부 외용제 조성물
WO2011086891A1 (fr) Composition pour faciliter de façon non invasive l'élimination d'un pigment cutané
KR20010060882A (ko) 미백용 피부외용제 조성물
KR101909533B1 (ko) 진세노사이드 ｆ１을 함유하는 피부 외용제 조성물
JP5797470B2 (ja) 皮膚沈着色素排出促進剤
CN101854909B (zh) 含有桔梗皂苷-d的皮肤美白剂
JP2006022090A (ja) ピロリドンカルボン酸亜鉛塩から成る炎症抑制剤
KR100415278B1 (ko) 향료를 이용한 미백 화장료 조성물
KR100472104B1 (ko) 미백용 피부외용제 조성물
KR102685191B1 (ko) 레코플라본 또는 이의 염을 포함하는 피부개선용 화장료 조성물
CN113226264A (zh) 用于减少内皮素-1分泌、干细胞因子合成和蛋白质羰基化的白松树皮提取物
US11780883B2 (en) Derived peptide of lactoferrin and method thereof for promoting and/or increasing lipid synthesis
KR100821482B1 (ko) 미백용 피부 외용제 조성물

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11732766

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP